William Thorndike's 2012 study of eight outsider CEOs revealed that compounding shareholder wealth is a capital-allocation discipline — not an operating one. Titan Biotech's FY25 audited numbers fit the five-choice template.
Tversky & Kahneman's 1983 conjunction fallacy explains why Indian retail investors judge five-leg bull stories as more probable than one-leg theses — and how single-leg corporate behaviour like Titan Biotech Ltd's audited FY25 numbers illustrates the opposite discipline.
James Montier's Modified C-Score is a six-variable forensic detector for accounting manipulation. We decode all six variables, contrast a disciplined manufacturer with a generic red-flag profile, and show how Titan Biotech FY25's audited numbers score 0/6 — an educational illustration only, not a buy/sell recommendation.